It is never too early to think about the ethical issues that can arise from any new technology.

As new cancer drugs arrive, regulators and doctors still struggle with when to use drugs based on earlier data and when to wait for survival data. #ASCO23

The U.K. will launch a $50 million pilot program to explore how new weight-loss drugs can be given to more people outside hospitals.

In the new book “If I Betray These Words,” I tell the story, with Simon Talbot, of Rita Gallardo (a pseudonym): Deployed in the desert Middle East, confined to a military base ringed by Hesco barriers and razor wire, Dr. Rita Gallardo’s only escape f

Merck sued the U.S. government, seeking an injunction to block the drug-price negotiation program contained in the Inflation Reduction Act.

“I think we need to vote," said the FDA's oncology chief, Richard Pazdur. "We have to make a binary decision at FDA whether to or not to approve. If we…

Giving an AstraZeneca drug called Tagrisso to patients with non-small cell lung cancer who have had their tumors removed reduced the risk of death by 51%.

Despite pressure from Congress and advocates, Medicare is not changing its coverage plan for new Alzheimer's drugs anytime soon.

Coherus BioSciences plans to sell a Humira biosimilar at a steep discount and will work with Mark Cuban’s generic drug company to sell it to consumers.

A U.S. appeals court ruled that Purdue Pharma can shield its owners from lawsuits over the company's role in the opioid crisis as part of a bankruptcy settlement.

A report by nonpartisan congressional researchers suggests there are at least some parts of the new drug pricing law that drugmakers cannot challenge.

The European Medicines Agency recommended revoking marketing authorization for a Novartis sickle cell disease drug called Adakveo.

Underrepresentation of population subgroups in clinical research is bad for the health of Americans.

A small club of billionaires is using unorthodox tactics — and piles of cash and connections — to campaign to rein in hospital prices.

The FDA delayed its decision on a gene therapy for Duchenne muscular dystrophy and is leaning toward clearing it for only a subset of younger kids.

The administration is planning a yearly audit to verify prices drugmakers charge on a handful of the costliest prescriptions covered by Medicaid.

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity.

A FDA advisory panel voted against approving an investigational treatment from Intercept Pharmaceuticals for treating NASH.

The U.S. Supreme Court upheld a ruling that Amgen failed to disclose sufficient information about patent claims for its cholesterol drug Repatha.

A federal appeals court panel heard arguments in a case that could determine the future of a commonly used abortion pill.

The FTC's suit to block Amgen from acquiring Horizon Therapeutics cast a spotlight on a practice known as bundling.

The White House drug czar is summoning naloxone makers for a meeting to address the price of naloxone, a medication used to reverse opioid overdoses.

The FTC is expected to file a lawsuit to block Amgen from acquiring Horizon Therapeutics, arguing the $27.8 billion deal would hamper innovation.

The clinic closures signaled an abrupt halt to a scramble to dominate the North American market for administering ketamine.

The FDA approved a new kind of drug to treat hot flashes, which could offer relief to women who do not want to take hormone therapy.

The U.S. Senate health committee passed a package of bills aimed at speeding generic drug competition and reining in pharmacy benefit managers.

An advisory panel of independent experts voted unanimously that the FDA should approve the first over-the-counter birth control pill.

Gilead Sciences prevailed in a closely watched battle with the U.S. government over the rights to groundbreaking HIV prevention pills.

Thanks to advances in science, notably the completion of the Human Genome Project 20 years ago, we are able to treat diseases more effectively than ever before. Researchers have more sophisticated tools not only to identify new drug targets, but also

The number of layoffs in the U.S. pharmaceutical industry continued at a brisk rate last month as another 600 jobs were eliminated.